Mangalam Drugs & Organics Ltd (nse:MANGALAM) Share Price

Company Profile

Business description
Mangalam Drugs & Organics Ltd commenced its manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. The company is engaged in the manufacture and sale of APIs for various therapeutic segments, including anti-malaria, anti-retroviral, and anti-hypertensive. It is approved by the Bill Clinton Foundation. The company is actively producing Pyronaridine Tetraphosphate, a new API used in antimalarial treatments. The company has received prequalification from the World Health Organization (WHO) for both micronized and non-micronized forms of Pyronaridine Phosphate.
Contact
P. D'Mello Road
Rupam Building, 3rd Floor, No. 239
Near General Post Office
MumbaiMH400001
IND
T: +91 2222616200
https://www.mangalamdrugs.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
480

Recommended

Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.

Ananya Chag | 27 April 2026

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.

Malik Ahmed Khan, CFA | 24 April 2026

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.

Mark Taylor | 24 April 2026

Index	Last price	Change	% Change
All Ordinaries	8,935.00	14.40	-0.16%
CAC 40	8,112.92	29.00	-0.36%
DAX 40	24,033.15	50.38	-0.21%
Dow JONES (US)	49,149.78	18.01	-0.04%
FTSE 100	10,310.41	10.68	-0.10%
HKSE	25,679.78	245.87	-0.95%
NASDAQ	24,700.74	186.36	-0.75%
Nikkei 225	59,917.46	619.90	-1.02%
NZX 50 Index	12,764.40	110.54	-0.86%
S&P 500	7,139.99	33.92	-0.47%
S&P/ASX 200	8,710.70	10.50	-0.12%
SSE Composite Index	4,078.64	7.71	-0.19%